Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease

J Crohns Colitis. 2016 Oct;10(10):1224-36. doi: 10.1093/ecco-jcc/jjw054. Epub 2016 Feb 29.

Abstract

Background: Little is known of the clinical outcome of patients with older-onset inflammatory bowel disease [IBD]. We performed a systematic review to determine phenotype and outcomes of older-onset IBD compared with younger-onset subjects.

Methods: A systematic search of Embase and Medline up to June 2015 identified studies investigating phenotype and outcomes of older-onset [diagnosed at age ≥ 50 years] Crohn's disease [CD] and ulcerative colitis [UC] subjects. Pooled analyses of disease phenotype, medication use, and disease-related surgery were calculated.

Results: We analysed findings from 43 studies comprising 8274 older-onset and 34641 younger-onset IBD subjects. Compared with younger-onset patients, older-onset CD patients were more likely to have colonic disease (odds ratio [OR] 2.56, 95% confidence interval [CI] 1.88 - 3.48) and inflammatory behaviour [OR 1.19, 95% CI 1.07 - 1.33], and less likely to have penetrating disease or perianal involvement. More older-onset UC patients had left-sided colitis [OR 1.49, 95% CI 1.18 - 1.88]. Although fewer older-onset IBD patients received immunomodulators [CD: OR 0.44; UC: OR 0.60] or biologicals [CD: OR 0.34; UC: OR 0.41], older-onset CD was similar in the need for surgery [OR 0.70, 95% CI 0.40 - 1.22] whereas more older-onset UC patients underwent surgery [OR 1.36, 95% CI 1.18 - 1.57].

Conclusions: Elderly IBD patients present with less complicated disease, but have similar or higher rates of surgery than non-elderly patients. Whether this reflects a non-benign disease course, physicians' reluctance to employ immunomodulators, or both, merits further study which is essential for improving the care of IBD in the elderly.

Keywords: Older-onset IBD; natural history; outcomes; phenotype.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Age of Onset
  • Aged
  • Aged, 80 and over
  • Combined Modality Therapy
  • Disease Progression
  • Humans
  • Immunologic Factors / therapeutic use
  • Inflammatory Bowel Diseases* / diagnosis
  • Inflammatory Bowel Diseases* / drug therapy
  • Inflammatory Bowel Diseases* / pathology
  • Inflammatory Bowel Diseases* / therapy
  • Middle Aged
  • Models, Statistical
  • Phenotype*
  • Prognosis

Substances

  • Immunologic Factors